Page 91 - Haematologica - Vol. 105 n. 6 - June 2020
P. 91
PRIMA-1Met and AZA combination in TP53-mutant MDS/AML
AB
C
DE
Figure 7. The antiproliferative effect of PRIMA-1Met (APR-246, APR) + azacitidine (AZA) combination is related to downregulation of the FLT3 pathway. (A) Gene enrichment plots and heatmaps representing the FLT3 activated pathway (Valk, FLT3-ITD) in APR versus untreated SKM1 cells and APR + AZA versus AZA-treated cells. (B) Real-time quantitative polymerase chain reaction analysis of gene expression by FLT3 and FLT3-L with APR, AZA, or APR + AZA relative to the untreated control. (C) Absolute numbers of untreated and APR + AZA-treated SKM1 cells exposed to increasing concentrations of FLT3-L. (D) Proliferation of SKM1 cells treated with APR, AZA, or the combination APR + AZA relative to controls, without or with 10 ng/mL FLT3 ligand (FLT3-L). (E) Proportion of Annexin V-positive SKM1 cells at day 3 following treatment with APR, AZA, or the combination of APR + AZA, with or without FLT3L. *P<0.05, **P<0.01, ***P<0.001.
haematologica | 2020; 105(6)
1549
